Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $37.00

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $37.00.

Several equities research analysts have weighed in on MAZE shares. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 18th. BTIG Research upped their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. JPMorgan Chase & Co. boosted their price target on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a report on Monday, September 29th. Finally, Wedbush upped their price target on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, November 7th.

Insider Activity at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth about $66,874,000. Frazier Life Sciences Management L.P. raised its stake in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares in the last quarter. ARCH Venture Management LLC purchased a new stake in Maze Therapeutics in the first quarter worth about $45,362,000. Matrix Capital Management Company LP purchased a new stake in Maze Therapeutics in the first quarter worth about $27,373,000. Finally, Alphabet Inc. bought a new stake in Maze Therapeutics during the 1st quarter valued at approximately $26,561,000.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $32.56 on Monday. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $34.29. The company has a fifty day moving average of $26.86 and a 200-day moving average of $17.75. The company has a market capitalization of $1.57 billion and a P/E ratio of -1.56.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.